{
  "docId": "019de075-3db6-70cc-be39-8d329d3330a5",
  "docSlug": "9a5a1cb2d23439a1f3fda2d5175b10b5",
  "documentTitle": "Alkermes | Results Presentation Deck | 17 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 17,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 24,
  "notes": "Includes a disclaimer regarding the separation of the oncology business and a footnote about non-GAAP reconciliation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-3db6-70cc-be39-8d329d3330a5/7",
  "deckHref": "/decks/019de075-3db6-70cc-be39-8d329d3330a5",
  "deckJsonHref": "/decks/019de075-3db6-70cc-be39-8d329d3330a5.json",
  "deckAnchorHref": "/decks/019de075-3db6-70cc-be39-8d329d3330a5#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.62,
        "y": 0.75
      },
      "kind": "disclaimer",
      "text": "Financial Expectations for Year Ending Dec. 31, 2023 and Janssen royalty expectations... The Company expressly disclaims any obligation to update or reaffirm these expectations.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c623ed1f-df93-430a-8e0c-f43191e39a84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.35,
        "x": 0.62,
        "y": 0.2
      },
      "kind": "list",
      "text": "Total Revenues Breakdown: Expected net sales of proprietary products (VIVITROL, ARISTADA, LYBALVI) and Janssen royalty expectations.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9b5fb84-e612-44f9-9873-9c6aa85664d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.06,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "The Company's 2023 financial expectations continue to reflect Alkermes' combined neuroscience and oncology business for the full year.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec02f30a-b376-406e-8f29-987474b331d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.55,
        "x": 0.06,
        "y": 0.205
      },
      "kind": "table",
      "text": "Financial table showing line items like Total Revenues, COGS, R&D, SG&A, and Net Income with 2023 guidance ranges.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d051f2d6-11e6-4b81-9d1b-ca4f75865136",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "Alkermes: 2023 Financial Expectations",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fea8845d-139a-4d95-b6ed-ca75484daa76",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 4,
      "beatId": "d5f4e08a-d337-402e-8a2b-d07acbe069eb",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Key Performance Indicator Overview",
      "beatSlug": null,
      "evidence": "Slides 4-13 provide an overview of the company's financial results, revenue summary, and product performance.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7aacdd12-f2ee-4912-b182-10d9fd1385f9",
      "evidence": "The presentation highlights the company's topline growth and diversification, implying that not achieving this growth would have negative consequences.",
      "position": 0,
      "objective": "What are the implications of not achieving topline growth and diversification?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}